 Percutaneous urinary diversion patients hormone-refractory prostate cancer Twenty-two patients hormone-refractory prostate cancer underwent percutaneous urinary diversion time metastatic disease Eleven patients postnephrostomy therapy median survival time patients nineteen days Overall percent patients lifetime hospital hospital required rehospitalization patients median survival time group patients expected survival similar patients ureteral obstruction percutaneous urinary diversion quality life patients